14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
MGTX vs ACHV: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, MeiraGTx Holdings plc (MGTX) is the stronger overall head-to-head candidate over Achieve Life Sciences, Inc. (ACHV) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MGTX carries a Unified Composite Score of 43.7/100 (HOLD) at $8.82 (64.1x Forward P/E, 46.3% operating margin), whereas ACHV carries 56.6/100 (HOLD) at $6.78 (35.3x Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While ACHV currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. MGTX 43.7/100 HOLD), MGTX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (46.3% vs. 0.0% operating margin) and revenue trajectory (+8608.6% vs. +0.0% YoY).
Technical & Structure Timing Caution: MGTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.5); meanwhile ACHV trades in a Neutral technical trend (BREAKOUT options phase, RSI 48.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MGTX vs ACHV. Trailing 12-month operating profitability (MGTX 46.3% vs ACHV 0.0%) and valuation multiples (MGTX 64.1x vs ACHV 35.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $692.8M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MGTX vs ACHV Key Questions & Quantitative Answers
As of Nov 16, 2026, MeiraGTx Holdings plc (MGTX) is the stronger overall head-to-head candidate over Achieve Life Sciences, Inc. (ACHV) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MGTX carries a Unified Composite Score of 43.7/100 (HOLD) at $8.82 (64.1x Forward P/E, 46.3% operating margin), whereas ACHV carries 56.6/100 (HOLD) at $6.78 (35.3x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ACHV currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. MGTX 43.7/100 HOLD), MGTX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (46.3% vs. 0.0% operating margin) and revenue trajectory (+8608.6% vs. +0.0% YoY). Technical & Structure Timing Caution: MGTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.5); meanwhile ACHV trades in a Neutral technical trend (BREAKOUT options phase, RSI 48.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MGTX leads the Growth & Scale pillar: MGTX posts +8608.6% YoY revenue growth and +0.0% YoY earnings growth on $398M TTM revenue (97.9% gross margin, 46.3% operating margin), compared with ACHV at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MGTX generates $398M in USD-normalized revenue versus N/A for ACHV. In operating R&D and SG&A reinvestment, MGTX deploys 51.6% of Rev ($205M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACHV.
ACHV screens cheaper on headline valuation multiples. MGTX trades at 64.1x Forward P/E, 10.1x Trailing P/E, N/M PEG, and 2.0x EV/Revenue (-7.0% FCF margin), whereas ACHV trades at 35.3x Forward P/E, 35.3x Trailing P/E, 17.68x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MGTX (72.2% ROE) versus ACHV (-845.0% ROE) capital efficiency.
In options market volatility and institutional positioning, MGTX carries 52.9% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.65β · 69% Vol realized risk). By comparison, ACHV carries 88.3% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.